SABCS 2022: Trastuzumab Deruxtecan Extends Survival Over Chemotherapy for Patients With HER2-Positive Metastatic Breast Cancer
Data confirm clinical benefit of T-DXd over conventional chemotherapy-based regimens in patients treated with trastuzumab emtansine
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.